Shining new light diabetes treatment

Shining new light on diabetes treatment

4:50 AM, 15th April 2016
Shining new light on diabetes treatment

BIRMINGHAM, UK: University of Birmingham researchers have developed a light-activated tool to show how drugs need to be adapted to combat type 2 diabetes.

The study is published in the journal Angewandte Chemie, provides insight into the signalling process of receptors in cells.

The team behind the research believe their findings could pave the way for a new generation of anti-diabetic drugs that are activated by the presence of either blue or ultra-violet light.

Dr David Hodson, from the Institute of Metabolism and Systems Research at the University of Birmingham, said, “Current treatment for type 2 diabetes hinges on dietary and medical intervention to restore the body’s ability to release insulin. Over the past 10 years, a class of drugs termed incretin mimetics have been developed and have revolutionised the treatment of type 2 diabetes.”

“The challenge now is to make such interventions more targeted. At the moment, the approach is equivalent to using a sledgehammer to crack a nut. By advancing our understanding of receptors in cells we can design more efficient drugs and reduce the risk of side effects. Light-activated technologies that change the shape of drugs are really interesting, non-invasive ways of getting the treatment to the right place, at the right time,” David said.

Current drugs target the glucagon-like peptide 1 (GLP-1) receptor, a G-protein coupled receptor. However, much remains unknown about how this receptor works, limiting production of newer, safer and more effective anti-diabetics.

In particular, the GLP-1R possesses a back door, termed an allosteric site. This site is of particular interest for the development of drugs that demonstrate superior selectivity. However, drug discovery efforts are hampered by lack of tools to understand how the allosteric site works.

To circumvent this problem, Dr Hodson, alongside professor Dirk Trauner and Dr Johannes Broichhagen at Ludwig Maximilian University of Munich (LMU), employed a combination of synthetic chemistry, biology and high-throughput screening to produce a novel anti-diabetic whose activity can be precisely controlled with light.

Their new drug, PhotoETP, shows that the structure needs to be twisted to fit into the allosteric site, but extended to activate signalling and insulin secretion.

With this information, a new generation of light-activated anti-diabetics can now be produced that allow better control over blood glucose levels with fewer side effects.

Type 2 diabetes currently affects almost 10 percent of the adult population. This disease state, typified by failure to produce enough insulin, leads to elevated glucose levels. The latter drive a range of complications including heart disease, nerve problems, blindness and cancer and cost the NHS £1 million per day to treat.

© University of Birmingham News

Related Topic:

Chemistry trick paves way for safer diabetes medication



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Praxair to supply oxygen for glassmaker Libbey in Netherlands

DANBURY, US: Praxair Inc said it has agreed with Libbey, one of the largest glassware and tableware manufacturers globally, to supply it with Praxair& ...

Read more
BASF improves power capacity with battery material license in US

ISELIN/LEXINGTON, US: BASF SE said that has been granted a license under the intellectual property of CAMX Power LLC (CAMX) relating to the CAMX suite ...

Read more
Albemarle CFO resumes work following temporary medical leave

BATON ROUGE, US: Albemarle Corporation said that senior vice president and chief financial officer (CFO) Scott Tozier has returned to work following a ...

Read more
Israel Chemicals appoints new chief operating officer

TEL AVIV, ISRAEL: Israel Chemicals Ltd (ICL) has appointed Charlie Weidhas, currently president of industrial products, as new chief operating officer ...

Read more
Pembina, PIC to evaluate world-scale polypropylene facility in Alberta

CALGARY, CANADA: Pembina Pipeline Corporation (Pembina) announced the joint feasibility study with the Petrochemical Industries Company KSC (PIC), a s ...

Read more
Clariant acquires stake in South Korea cosmetics’ ingredients maker

MUTTENZ, GERMANY: Clariant AG said it will acquire a 17 percent share in South Korea-headquartered BioSpectrum Inc, a developer and supplier of specia ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X